Genuro, a clinical‑stage biotech subsidiary of NRx Pharmaceuticals, presented its ALS‑focused program at the Moody Capital Disruptive Growth & Life Science Conference on Wednesday, September 9, 2026. The company said it aims to have a human‑grade antibody product ready for the clinic by July 2027, with bioreactor production expected to begin in January of that year. Clinical trial initiation is slated for 2027, and the company cites a possible FDA approval date as early as 2029.
Financially, Genuro is raising $5 million through a Regulation CF crowdfunding campaign administered by Moody Capital. The technology underpinning the drug has benefited from roughly €180 million of prior European R&D, mainly funded by the European Investment Fund, before the assets were acquired out of a Swiss bankruptcy. The U.S. defense appropriations bill for 2027 earmarks $80 million for ALS clinical trials, and Genuro estimates the total path to a market‑ready drug by 2029 at about $25 million. If approved, the U.S. government would receive a 3 % royalty on sales due to shared patents.
Scientifically, Genuro’s approach targets human endogenous retrovirus‑K (HERV‑K) envelope proteins, which are detected in the cerebrospinal fluid of more than 75 % of ALS patients and absent in non‑ALS controls. The company notes that a predecessor firm ran five clinical trials of an anti‑HERV‑W antibody in multiple sclerosis, treating over 400 patients with no reported safety issues. Genuro holds 25 approved patents globally and aims for roughly 100 by the time its lead compound reaches clinical trials, spanning seven patent families.
The presentation also highlighted the disease burden: ALS affects about 6,000 people annually in the United States, with a median survival of three to five years. Combat veterans and contact‑sport athletes face elevated risk, two to three times higher than the general population. The FDA’s accelerated approval pathway, which can rely on biomarker reductions such as neurofilament light chain, was cited as a potential route, referencing the precedent set by QALSODY for a subset of SOD1‑mutation ALS patients.
Key individuals mentioned include CEO Jonathan Javitt, who earned a biochemistry degree from Princeton in 1978, and scientific advisory board chair Arnie Levine, who taught molecular biology to Javitt at Princeton in 1977. Other noted figures are Hervé Perron, chief scientist; Dr. Avindra Nath of the NIH; Professor Marion Leboyer of Inserm; and several industry veterans involved in manufacturing and regulatory affairs.
